Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.

Abstract

High-dose methotrexate with leucovorin rescue plus cyclophosphamide resulted in a 66.6% objective response rate with a 50% complete response rate. These preliminary results are higher than our previous results with melphalan alone or actinomycin D, 5-fluorouracil, and cyclophosphamide in women with advanced ovarian adenocarcinoma. Circulating ovarian cystadenocarcinoma-associated antigen serum levels were positive in 69.8% of patients and correlated with response to chemotherapy in 70% of patients. To date, all of the patients with advanced ovarian adenocarcinoma were found to have elevated galactosyltransferase levels. Galactosyltransferase levels correlated with response to therapy in the first five patients followed serially.

• Authors: M S Piver, J J Barlow, M Bhattacharya
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 63 Issue 2 Pg. 265-7 (Feb 1979) ISSN: 0361-5960 [Print] United States
• PMID: 376133 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Antigens, Neoplasm
• Antineoplastic Agents
• Cyclophosphamide
• Galactosyltransferases
• Leucovorin
• Methotrexate

Topics

• Adenocarcinoma (diagnosis, drug therapy)
• Antigens, Neoplasm (analysis)
• Antineoplastic Agents (administration & dosage)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage)
• Drug Therapy, Combination
• Female
• Galactosyltransferases (blood)
• Humans
• Leucovorin (administration & dosage)
• Methotrexate (administration & dosage)
• Ovarian Neoplasms (diagnosis, drug therapy)